Protagonist Therapeutics Restructures Takeda Partnership for Rusfertide | Boston Capital Investment Club posted on the topic | LinkedIn Major BD Reset: Protagonist Therapeutics Restructures Takeda Partnership Around Rusfertide A significant partnership restructuring has just taken place in the hematology space. Protagonist Therapeuti...

Major BD Reset: Protagonist Therapeutics Restructures Takeda Partnership Around Rusfertide

A significant partnership restructuring has just taken place in the hematology space.

www.linkedin.com/posts/boston...
#BCIC #Biotech #Takeda #ProtagonistTherapeutics #Rusfertide #Hematology #PharmaDeals

Protagonist and Takeda Report Positive Phase 3 Results in Rare Blood Cancer at ASCO 2025 VERIFY study meets all endpoints in polycythemia vera, supporting improved hematocrit control, reduced need for phlebotomy, and symptom relief Protagonist Th

#PTGX and #TAK report positive Phase 3 results for rusfertide in rare blood cancer PV at ASCO 2025! The data shows major progress in symptom control and disease management.
#ProtagonistTx #TakedaPharma
#Biotech #ProtagonistTherapeutics #RareDisease #PVResearch
prismmarketview.com/protagonist-...